41 Prostate Cancer Clinical Trials in Boston, NY (2026)

Q: How do I join a clinical trial in Boston?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Boston research site will contact you.

Recruiting Prostate Cancer Studies in Boston

NCT05926102Recruiting

The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)

Prostate cancer is the most common non-skin cancer among Veterans and the second leading cause of male cancer death. Current methods of screening men for prostate cancer are inaccurate and cannot iden...

Boston, NY5,000 participantsVA Office of Research and Development

View Study Details

NCT04706663Recruiting

Precision-Based Genomics in Prostate Cancer

Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s...

Boston, NY2,000 participantsNational Cancer Institute (NCI)

View Study Details

NCT06398639Recruiting

Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer

The goal of this clinical trial is to evaluate a screening method to detect clinically relevant prostate cancer. This clinical trial is using genetic data to determine a man's risk of cancer, together...

Boston, NY1,500 participantsAdam S. Kibel, MD

View Study Details

NCT06855277Recruiting

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

The purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), ...

Boston, NY940 participantsNovartis Pharmaceuticals

View Study Details

NCT05155501Recruiting

Clinical Trial of Approaches to Prostate Cancer Surgery

This is a prospective, randomized controlled trial to compare cancer control and health-related quality of life following pelvic fascia-sparing radical prostatectomy versus standard radical prostatect...

Boston, NY600 participantsWeill Medical College of Cornell University

View Study Details

NCT06579417Recruiting

ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer

This is a multicenter, multinational trial to evaluate advanced MRI techniques for improved detection of clinically significant prostate cancer (csPCa). The study will enroll 500 participants at 5 cli...

Boston, NY500 participantsUniversity of California, San Diego

View Study Details

NCT04787744Recruiting

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-...

Boston, NY464 participantsVA Office of Research and Development

View Study Details

NCT04472338Recruiting

Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study

This study investigates ways to detect prostate cancer earlier in people at genetic risk for disease that forms, grows, or spreads quickly (aggressive). Studying samples of blood, urine, and/or tissue...

Boston, NY450 participantsUniversity of Washington

View Study Details

NCT03972657Recruiting

A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

The main purpose of this study is to determine the safety, tolerability (how your body reacts to the drug) and effectiveness (ability to treat your cancer) of REGN5678 alone, or in combination with ce...

Boston, NY345 participantsRegeneron Pharmaceuticals

View Study Details

NCT04812366Recruiting

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response. Each participant will be...

Boston, NY315 participantsUniversity of British Columbia

View Study Details

NCT07336446Recruiting

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmaco...

Boston, NY300 participantsAstraZeneca

View Study Details

NCT01961713Recruiting

Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy

This study will evaluate a method to detect tumor cells that are circulating in the blood without getting a biopsy. The investigators already know from other studies that cancer tumors shed a small nu...

Boston, NY200 participantsMassachusetts General Hospital

View Study Details

NCT06800313Recruiting

A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Assessment of the safety and efficacy of HLD-0915 as monotherapy in patients with metastatic castration resistant prostate cancer (mCRPC) that have progressed on prior systemic therapies, once a recom...

Boston, NY190 participantsHalda Therapeutics OpCo, Inc.

View Study Details

NCT07206056Recruiting

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of car...

Boston, NY188 participantsNovartis Pharmaceuticals

View Study Details

NCT06202820Recruiting

CV CARE: CardioVascular Care in PC Patients

This research is being done to test a program to assess and manage reversible cardiovascular (CV) risk factors in participants with prostate cancer starting androgen deprivation therapy (ADT), with th...

Boston, NY180 participantsDana-Farber Cancer Institute

View Study Details

NCT07181161Recruiting

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer....

Boston, NY177 participantsAstraZeneca

View Study Details

NCT06991556Recruiting

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen...

Boston, NY150 participantsNovartis Pharmaceuticals

View Study Details

NCT04363164Recruiting

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to dete...

Boston, NY150 participantsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

View Study Details

NCT06067841Recruiting

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer....

Boston, NY140 participantsBristol-Myers Squibb

View Study Details

NCT06879041Recruiting

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275....

Boston, NY136 participantsAstraZeneca

View Study Details

NCT05804318Recruiting

Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer

This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will ...

Boston, NY132 participantsVarian, a Siemens Healthineers Company

View Study Details

NCT06844383Recruiting

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with metastatic castration-resistant prostate can...

Boston, NY126 participantsProstate Cancer Clinical Trials Consortium

View Study Details

NCT05765500Recruiting

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

This study is testing the way that approved androgen deprivation therapy treatments, Leuprolide and Relugolix, for prostate cancer affect quality of life, blood levels, cholesterol, and blood sugar. T...

Boston, NY110 participantsDana-Farber Cancer Institute

View Study Details

NCT04545957Recruiting

Jump: MR Simulation For Radiation Therapy Master Protocol

This is a master protocol for a prospective Phase I-II study evaluating feasibility and efficacy of incorporating magnetic resonance imaging (MRI) simulation into the planning of radiation treatments....

Boston, NY86 participantsBrigham and Women's Hospital

View Study Details

NCT06496256Recruiting

Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial

Barrigel is intended to temporarily position the anterior rectal wall away from the prostate or prostate bed during radiotherapy treatment for prostate cancer and, in creating this space, it is the in...

Boston, NY84 participantsPalette Life Sciences, Inc.

View Study Details

NCT06040125Recruiting

Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial

The purpose of this study is to determine whether a 16-week supervised, clinic-based circuit training intervention utilizing resistance and functional exercises and self-directed aerobic exercise will...

Boston, NY80 participantsDana-Farber Cancer Institute

View Study Details

NCT05488548Recruiting

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies...

Boston, NY75 participantsEpigenetix, Inc.

View Study Details

NCT05918263Recruiting

Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial

The purpose of this study is to determine whether a 12-week, home-based, virtually supervised exercise program will slow cancer progression of prostate cancer among men with prostate cancer at high-ri...

Boston, NY68 participantsFred Hutchinson Cancer Center

View Study Details

NCT06801236Recruiting

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC)....

Boston, NY67 participantsAcerand Therapeutics (Hong Kong) Limited

View Study Details

NCT06267729Recruiting

Study of AZD0754 in Participants With Metastatic Prostate Cancer

The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer....

Boston, NY60 participantsAstraZeneca

View Study Details

NCT06549465Recruiting

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

This is a three-part study evaluating the safety and efficacy of a PSMA-directed radioantibody (rosopatamab tetraxetan, conjugated to either In-111 or Ac-225). Part 1 will consist of one administratio...

Boston, NY60 participantsConvergent Therapeutics

View Study Details

NCT07140900Recruiting

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone....

Boston, NY60 participantsAmgen

View Study Details

NCT07244341Recruiting

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

This study will assess the safety and tolerability of valemetostat in combination with darolutamide in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC)....

Boston, NY60 participantsDaiichi Sankyo

View Study Details

NCT06957691Recruiting

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

The goal of this clinical trial is to learn if fezolinetant can treat hot flashes (vasomotor symptoms) in men with prostate cancer undergoing androgen deprivation therapy. The main questions it aims ...

Boston, NY60 participantsShehzad Basaria, M.D.

View Study Details

NCT04946370Recruiting

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

This is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that increases the immune ...

Boston, NY52 participantsWeill Medical College of Cornell University

View Study Details

NCT07192614Recruiting

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD6621. The study is split into differ...

Boston, NY52 participantsAstraZeneca

View Study Details

NCT06862856Recruiting

Flotufolastat F 18 PET in Men With Very Low PSA Recurrence

The purpose of this study is to assess detection rate of flotufolastat F 18 positron emission tomography (PET) for low prostate specific antigen (PSA) recurrence of prostate cancer (PC) following radi...

Boston, NY50 participantsMassachusetts General Hospital

View Study Details

NCT06062745Recruiting

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of advanced prostate cancer that...

Boston, NY30 participantsBrigham and Women's Hospital

View Study Details

NCT06099093Recruiting

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

The purpose of this research study is to see how well an imaging test, called 18FDCFPyL prostate specific membrane antigen (PSMA) positron emission tomography (PET), can show the extent of prostate ca...

Boston, NY30 participantsBrigham and Women's Hospital

View Study Details

NCT07393867Recruiting

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

This research study is for men with intermediate- or high-risk prostate cancer who are planning to receive hormone therapy and radiation treatment. The purpose of the study is to see whether a special...

Boston, NY23 participantsMartin T. King, MD, PhD

View Study Details

NCT06302595Recruiting

MRI Guided Prostate Biopsy

This study aims to assess the feasibility of magnetic resonance (MR) guided prostate biopsy using a needle holder frame. This frame is used to help position the needle used for the biopsy. The feasibi...

Boston, NY15 participantsBrigham and Women's Hospital

View Study Details

About Prostate Cancer Clinical Trials in Boston

Prostate cancer develops in the prostate gland and is one of the most common cancers in men. Many prostate cancers grow slowly, but some can be aggressive. Treatment options range from active surveillance to surgery, radiation, and hormone therapy.

There are currently 41 prostate cancer clinical trials recruiting participants in Boston, NY. These studies are seeking a combined 15,305 participants. Research is being sponsored by VA Office of Research and Development, National Cancer Institute (NCI), Adam S. Kibel, MD and 24 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Prostate Cancer Clinical Trials in Boston — FAQ

Are there prostate cancer clinical trials in Boston?

Yes, there are 41 prostate cancer clinical trials currently recruiting in Boston, NY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Boston?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Boston research site will contact you about next steps.

Are clinical trials in Boston free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Boston studies also compensate for your time and travel.

What prostate cancer treatments are being tested?

The 41 active trials in Boston are testing new therapies including novel drugs, biologics, and treatment approaches for prostate cancer.

Data updated July 13, 2026 from ClinicalTrials.gov